NASDAQ:ABUS - Arbutus Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.75 -0.05 (-0.86 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$5.75
Today's Range$5.65 - $5.80
52-Week Range$3.20 - $8.25
Volume97,383 shs
Average Volume146,986 shs
Market Capitalization$319.97 million
P/E Ratio-3.21
Dividend YieldN/A
Beta1.05

About Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma logoArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ABUS
CUSIPN/A
Phone604-419-3200

Debt

Debt-to-Equity Ratio0.01
Current Ratio16.86
Quick Ratio16.86

Price-To-Earnings

Trailing P/E Ratio-3.21
Forward P/E Ratio-3.86
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.70 million
Price / Sales29.65
Cash FlowN/A
Price / CashN/A
Book Value$2.07 per share
Price / Book2.78

Profitability

EPS (Most Recent Fiscal Year)($1.79)
Net Income$-84,410,000.00
Net Margins-705.09%
Return on Equity-61.50%
Return on Assets-36.20%

Miscellaneous

Employees130
Outstanding Shares55,170,000

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma (NASDAQ:ABUS) announced its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. The biopharmaceutical company had revenue of $1.40 million for the quarter. Arbutus Biopharma had a negative net margin of 705.09% and a negative return on equity of 61.50%. View Arbutus Biopharma's Earnings History.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Arbutus Biopharma.

What price target have analysts set for ABUS?

6 analysts have issued 1-year target prices for Arbutus Biopharma's shares. Their predictions range from $5.00 to $32.00. On average, they expect Arbutus Biopharma's share price to reach $12.3333 in the next year. View Analyst Ratings for Arbutus Biopharma.

Who are some of Arbutus Biopharma's key competitors?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the folowing people:
  • Dr. Mark Joseph Murray, Pres, CEO & Director (Age 69)
  • Dr. Peter Lutwyche Ph.D., Chief Technology Officer (Age 52)
  • Dr. Michael J. Sofia Ph.D., Chief Scientific Officer (Age 60)
  • Dr. Elizabeth Howard Ph.D., J.D., Exec. VP & Gen. Counsel (Age 64)
  • Mr. Koert VandenEnden C.A., C.P.A., Interim CFO & VP of Fin. (Age 39)

Has Arbutus Biopharma been receiving favorable news coverage?

Media headlines about ABUS stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arbutus Biopharma earned a media sentiment score of 0.20 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.64 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Foresite Capital Management IV LLC (2.69%), BlackRock Inc. (1.25%), JPMorgan Chase & Co. (0.40%), Victory Capital Management Inc. (0.30%), Eversept Partners LLC (0.21%) and Citadel Advisors LLC (0.12%). View Institutional Ownership Trends for Arbutus Biopharma.

Which major investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for Arbutus Biopharma.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was acquired by a variety of institutional investors in the last quarter, including Foresite Capital Management IV LLC, JPMorgan Chase & Co., Citadel Advisors LLC, DekaBank Deutsche Girozentrale, Victory Capital Management Inc. and Eversept Partners LLC. View Insider Buying and Selling for Arbutus Biopharma.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $5.75.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $319.97 million and generates $10.70 million in revenue each year. The biopharmaceutical company earns $-84,410,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. Arbutus Biopharma employs 130 workers across the globe.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]


MarketBeat Community Rating for Arbutus Biopharma (ABUS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  462
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arbutus Biopharma (NASDAQ:ABUS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Arbutus Biopharma in the last 12 months. Their average twelve-month price target is $12.3333, suggesting that the stock has a possible upside of 114.49%. The high price target for ABUS is $32.00 and the low price target for ABUS is $5.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.832.83
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.3333$12.3750$12.50$13.00
Price Target Upside: 114.49% upside135.71% upside140.38% upside116.67% upside

Arbutus Biopharma (NASDAQ:ABUS) Consensus Price Target History

Price Target History for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ:ABUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018Chardan CapitalReiterated RatingBuy$8.00LowView Rating Details
3/19/2018WedbushDowngradeOutperform ➝ Neutral$9.00 ➝ $6.00MediumView Rating Details
1/5/2018B. RileyInitiated CoverageBuy ➝ Buy$10.00MediumView Rating Details
11/7/2017Leerink SwannReiterated RatingMarket Perform$4.00 ➝ $5.00N/AView Rating Details
10/4/2017JMP SecuritiesReiterated RatingOutperform$12.00 ➝ $13.00HighView Rating Details
6/2/2017Ladenburg ThalmannInitiated CoverageBuy$32.00LowView Rating Details
1/9/2017Bloom BurtonUpgradeAccumulate ➝ BuyN/AView Rating Details
8/21/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Arbutus Biopharma (NASDAQ:ABUS) Earnings History and Estimates Chart

Earnings by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ:ABUS) Earnings Estimates

2018 EPS Consensus Estimate: ($1.60)
2019 EPS Consensus Estimate: ($1.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.42)($0.32)($0.38)
Q2 20183($0.44)($0.38)($0.40)
Q3 20183($0.44)($0.33)($0.38)
Q4 20183($0.63)($0.34)($0.44)
Q1 20192($0.46)($0.38)($0.42)
Q2 20192($0.46)($0.36)($0.41)
Q3 20192($0.47)($0.32)($0.40)
Q4 20192($0.66)($0.31)($0.49)

Arbutus Biopharma (NASDAQ ABUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
5/3/20183/31/2018($0.39)($0.36)$1.40 millionViewN/AView Earnings Details
3/14/2018After Market($0.39)($0.90)$0.70 million$2.50 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.38)($0.17)$0.79 million$6.90 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.35)($0.28)$0.68 million$1.00 millionViewN/AView Earnings Details
5/4/20173/31/2017($0.30)($0.34)$7.50 million$0.20 millionViewListenView Earnings Details
3/21/2017Q4 2016($0.38)($0.38)$0.76 million($0.20) millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.53)($0.31)$0.44 million$0.70 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.35)($0.35)$0.99 million$0.30 millionViewN/AView Earnings Details
5/4/2016Q1 2016($0.37)($0.31)$1.25 million$0.60 millionViewN/AView Earnings Details
3/9/2016Q4 2015($0.39)$0.31$2.55 million$12.71 millionViewN/AView Earnings Details
11/5/2015Q3 2015($0.31)($0.42)$3.37 million$4.10 millionViewN/AView Earnings Details
8/5/2015Q2($0.25)($0.20)$3.77 million$3.40 millionViewN/AView Earnings Details
5/6/2015Q1 2015($0.39)($0.40)$3.55 million$4.70 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.32)($0.27)$6.12 million$4.40 millionViewN/AView Earnings Details
11/6/2014Q314($0.40)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$3.72 million$1.80 millionViewN/AView Earnings Details
5/14/2014Q1 2014$0.40($0.22)$18.55 million$4.43 millionViewN/AView Earnings Details
3/6/2014Q4 2013($0.02)($0.07)$7.57 million$7.60 millionViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
11/13/2013Q3 2013($0.03)($0.24)$7.50 million$2.91 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.24)($0.21)$2.50 million$2.82 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.14)($0.18)$3.00 million$2.16 millionViewN/AView Earnings Details
3/27/2013Q4 2012($0.07)($0.38)ViewN/AView Earnings Details
12/18/2012Q3 2012($0.07)($0.12)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.16)($0.19)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.17)($0.25)ViewN/AView Earnings Details
3/27/2012Q4 2011$0.20($0.16)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.30)($0.12)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.31)($0.35)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.36)($0.31)ViewN/AView Earnings Details
3/17/2010Q4 2009($0.05)ViewN/AView Earnings Details
3/24/2009Q4 2008($0.06)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.11)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.14)ViewN/AView Earnings Details
5/14/2008Q1 2008($0.02)ViewN/AView Earnings Details
3/31/2008Q4 2007$0.01ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Arbutus Biopharma (NASDAQ:ABUS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Arbutus Biopharma (NASDAQ ABUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 33.30%
Insider Trading History for Arbutus Biopharma (NASDAQ:ABUS)
Institutional Ownership by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ ABUS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/3/2017Michael J SofiaInsiderSell10,000$8.00$80,000.00View SEC Filing  
8/15/2017Michael J SofiaInsiderSell30,000$3.70$111,000.001,563,403View SEC Filing  
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.001,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arbutus Biopharma (NASDAQ ABUS) News Headlines

Source:
DateHeadline
Arbutus Biopharma (ABUS) Given Consensus Recommendation of "Buy" by AnalystsArbutus Biopharma (ABUS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 25 at 1:40 PM
Arbutus Biopharma (ABUS) Upgraded at BidaskClubArbutus Biopharma (ABUS) Upgraded at BidaskClub
www.americanbankingnews.com - May 16 at 4:50 PM
Zacks: Brokerages Anticipate Arbutus Biopharma (ABUS) Will Post Earnings of -$0.35 Per ShareZacks: Brokerages Anticipate Arbutus Biopharma (ABUS) Will Post Earnings of -$0.35 Per Share
www.americanbankingnews.com - May 13 at 10:40 AM
Q2 2018 EPS Estimates for Arbutus Biopharma (ABUS) Decreased by WedbushQ2 2018 EPS Estimates for Arbutus Biopharma (ABUS) Decreased by Wedbush
www.americanbankingnews.com - May 10 at 7:16 AM
Arbutus Biopharmas (ABUS) Buy Rating Reaffirmed at Chardan CapitalArbutus Biopharma's (ABUS) Buy Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - May 7 at 11:27 AM
Arbutus Biopharmas (ABUS) CEO Mark Murray on Q1 2018 Results - Earnings Call TranscriptArbutus Biopharma's (ABUS) CEO Mark Murray on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:42 PM
Arbutus Biopharma (ABUS) Lifted to Buy at BidaskClubArbutus Biopharma (ABUS) Lifted to Buy at BidaskClub
www.americanbankingnews.com - May 5 at 12:29 AM
Arbutus Biopharma (ABUS) Reports Q1 Loss of $0.36/ShareArbutus Biopharma (ABUS) Reports Q1 Loss of $0.36/Share
www.streetinsider.com - May 4 at 5:34 PM
Arbutus Biopharma (ABUS) Issues Quarterly  Earnings ResultsArbutus Biopharma (ABUS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 4 at 4:36 PM
BRIEF-Arbutus Reports Q1 Loss Per Share $0.36BRIEF-Arbutus Reports Q1 Loss Per Share $0.36
www.reuters.com - May 4 at 8:18 AM
Arbutus: 1Q Earnings SnapshotArbutus: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:18 AM
Arbutus Biopharma beats by $0.03, beats on revenueArbutus Biopharma beats by $0.03, beats on revenue
seekingalpha.com - May 3 at 5:25 PM
Arbutus Announces Corporate Update and First Quarter 2018 Financial ResultsArbutus Announces Corporate Update and First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 5:25 PM
Merck Teams With Moderna To Take On One Of The Toughest Targets In CancerMerck Teams With Moderna To Take On One Of The Toughest Targets In Cancer
finance.yahoo.com - May 3 at 5:25 PM
Arbutus Biopharma (ABUS) Upgraded at ValuEngineArbutus Biopharma (ABUS) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 11:41 PM
Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial ResultsArbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results
finance.yahoo.com - April 30 at 5:14 PM
Arbutus Biopharma (ABUS) Given Consensus Recommendation of "Buy" by BrokeragesArbutus Biopharma (ABUS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 30 at 1:36 PM
Zacks: Analysts Expect Arbutus Biopharma (ABUS) to Announce -$0.38 EPSZacks: Analysts Expect Arbutus Biopharma (ABUS) to Announce -$0.38 EPS
www.americanbankingnews.com - April 25 at 11:10 PM
Arbutus Biopharma (ABUS) to Release Quarterly Earnings on WednesdayArbutus Biopharma (ABUS) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 7:33 AM
Arbutus Biopharma (ABUS) Upgraded to "Hold" by BidaskClubArbutus Biopharma (ABUS) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - April 25 at 12:58 AM
Arbutus Biopharma (ABUS) Downgraded by Zacks Investment ResearchArbutus Biopharma (ABUS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 19 at 10:12 PM
BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics ...BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics ...
www.reuters.com - April 13 at 5:33 PM
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA ...Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA ...
globenewswire.com - April 13 at 5:33 PM
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at ...Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at ...
globenewswire.com - April 13 at 5:33 PM
Form 8-K Arbutus Biopharma Corp For: Apr 12Form 8-K Arbutus Biopharma Corp For: Apr 12
www.streetinsider.com - April 13 at 5:33 PM
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
finance.yahoo.com - April 12 at 5:39 PM
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic DiseasesArbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
finance.yahoo.com - April 11 at 5:32 PM
Zacks: Brokerages Anticipate Arbutus Biopharma (ABUS) Will Announce Earnings of -$0.38 Per ShareZacks: Brokerages Anticipate Arbutus Biopharma (ABUS) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - April 8 at 11:16 PM
Arbutus Biopharma (ABUS) Downgraded by ValuEngine to SellArbutus Biopharma (ABUS) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 5 at 6:52 PM
Arbutus Biopharma (ABUS) Receives Average Recommendation of "Hold" from AnalystsArbutus Biopharma (ABUS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 5 at 1:38 PM
Arbutus Biopharma (ABUS) Upgraded to Buy by ValuEngineArbutus Biopharma (ABUS) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - April 3 at 8:13 PM
Arbutus Biopharma (ABUS) Stock Rating Lowered by ValuEngineArbutus Biopharma (ABUS) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 1 at 2:04 PM
Arbutus Biopharma (ABUS) Cut to Sell at Zacks Investment ResearchArbutus Biopharma (ABUS) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM
BidaskClub Upgrades Arbutus Biopharma (ABUS) to "Hold"BidaskClub Upgrades Arbutus Biopharma (ABUS) to "Hold"
www.americanbankingnews.com - March 30 at 6:15 PM
Arbutus to Present HBV Data at 2018 EASL Liver MeetingArbutus to Present HBV Data at 2018 EASL Liver Meeting
finance.yahoo.com - March 29 at 8:26 AM
Arbutus Biopharma (ABUS) Rating Increased to Sell at ValuEngineArbutus Biopharma (ABUS) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
Arbutus Biopharma (ABUS) Rating Lowered to Sell at BidaskClubArbutus Biopharma (ABUS) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 1:56 PM
 Analysts Expect Arbutus Biopharma (ABUS) to Announce -$0.38 Earnings Per Share Analysts Expect Arbutus Biopharma (ABUS) to Announce -$0.38 Earnings Per Share
www.americanbankingnews.com - March 22 at 11:08 PM
Arbutus Biopharma (ABUS) Upgraded to "Hold" by Zacks Investment ResearchArbutus Biopharma (ABUS) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - March 22 at 4:32 PM
Wedbush Weighs in on Arbutus Biopharmas Q1 2018 Earnings (ABUS)Wedbush Weighs in on Arbutus Biopharma's Q1 2018 Earnings (ABUS)
www.americanbankingnews.com - March 22 at 9:24 AM
Edited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMTEdited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMT
finance.yahoo.com - March 22 at 8:24 AM
Edited Transcript of ABUS earnings conference call or presentation 14-Aug-12 8:30pm GMTEdited Transcript of ABUS earnings conference call or presentation 14-Aug-12 8:30pm GMT
finance.yahoo.com - March 22 at 8:24 AM
Wedbush Downgrades Arbutus Biopharma (ABUS) to Neutral Citing limited Upside in 2018 - StreetInsider.comWedbush Downgrades Arbutus Biopharma (ABUS) to Neutral Citing limited Upside in 2018 - StreetInsider.com
www.streetinsider.com - March 20 at 8:27 AM
Wedbush softens view on Arbutus on extended timeline for HBV candidatesWedbush softens view on Arbutus on extended timeline for HBV candidates
seekingalpha.com - March 19 at 5:18 PM
Wedbush Projects Limited Upside For Arbutus Shares This Year, Moves To SidelinesWedbush Projects Limited Upside For Arbutus Shares This Year, Moves To Sidelines
finance.yahoo.com - March 19 at 5:18 PM
Arbutus Biopharma (ABUS) Earns Buy Rating from Analysts at Chardan CapitalArbutus Biopharma (ABUS) Earns Buy Rating from Analysts at Chardan Capital
www.americanbankingnews.com - March 19 at 11:12 AM
Wedbush Lowers Arbutus Biopharma (ABUS) to NeutralWedbush Lowers Arbutus Biopharma (ABUS) to Neutral
www.americanbankingnews.com - March 19 at 10:59 AM
Chardan Capital Markets Resumes Arbutus Biopharma (ABUS) at Buy - StreetInsider.comChardan Capital Markets Resumes Arbutus Biopharma (ABUS) at Buy - StreetInsider.com
www.streetinsider.com - March 19 at 8:22 AM
B. Riley Brokers Cut Earnings Estimates for Arbutus Biopharma (ABUS)B. Riley Brokers Cut Earnings Estimates for Arbutus Biopharma (ABUS)
www.americanbankingnews.com - March 19 at 2:15 AM
Brokers Set Expectations for Arbutus Biopharmas Q1 2018 Earnings (ABUS)Brokers Set Expectations for Arbutus Biopharma's Q1 2018 Earnings (ABUS)
www.americanbankingnews.com - March 19 at 2:14 AM

SEC Filings

Arbutus Biopharma (NASDAQ:ABUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arbutus Biopharma (NASDAQ:ABUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arbutus Biopharma (NASDAQ ABUS) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.